Published in Curr Drug Targets on August 01, 2008
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59
Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab (2009) 2.81
Diacylglycerol kinase regulates tyrosinase expression and function in human melanocytes. J Invest Dermatol (2012) 1.43
Lipid binding domains: more than simple lipid effectors. J Lipid Res (2008) 1.10
The bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses. Org Lett (2009) 1.08
p23/Tmp21 associates with protein kinase Cdelta (PKCdelta) and modulates its apoptotic function. J Biol Chem (2011) 0.95
Emerging methodologies to investigate lipid-protein interactions. Integr Biol (Camb) (2012) 0.92
Some phorbol esters might partially resemble bryostatin 1 in their actions on LNCaP prostate cancer cells and U937 leukemia cells. Chembiochem (2011) 0.89
Probing the determinants of diacylglycerol binding affinity in the C1B domain of protein kinase Cα. J Mol Biol (2011) 0.88
Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action. Biochem Pharmacol (2012) 0.86
Characterization of the differential roles of the twin C1a and C1b domains of protein kinase C-delta. J Biol Chem (2008) 0.84
Charge density influences C1 domain ligand affinity and membrane interactions. Chembiochem (2014) 0.82
Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester. J Biol Chem (2012) 0.82
TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation. Curr Top Med Chem (2011) 0.81
N-methyl-substituted fluorescent DAG-indololactone isomers exhibit dramatic differences in membrane interactions and biological activity. Chembiochem (2011) 0.80
Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C. Bioorg Med Chem (2010) 0.79
Neuronal porosome lipidome. J Cell Mol Med (2014) 0.79
C1 Domain-targeted isophthalate derivatives induce cell elongation and cell cycle arrest in HeLa cells. PLoS One (2011) 0.79
The Novel PKCθ from Benchtop to Clinic. J Immunol Res (2015) 0.78
Molecular systems pharmacology: isoelectric focusing signature of protein kinase Cδ provides an integrated measure of its modulation in response to ligands. J Med Chem (2014) 0.77
Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships. J Nat Prod (2015) 0.76
Structural Basis for the Failure of the C1 Domain of Ras Guanine Nucleotide Releasing Protein 2 (RasGRP2) to Bind Phorbol Ester with High Affinity. J Biol Chem (2016) 0.76
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains. J Med Chem (2014) 0.76
Protein kinase C: an attractive target for cancer therapy. Cancers (Basel) (2011) 0.75
Protein kinase C in cancer: The top five unanswered questions. Mol Carcinog (2017) 0.75
Polar 3-alkylidene-5-pivaloyloxymethyl-5'-hydroxymethyl-gamma-lactones as protein kinase C ligands and antitumor agents. Bioorg Med Chem Lett (2009) 0.75
The C1 domain of Vav3, a novel potential therapeutic target. Cell Signal (2017) 0.75
PKC in Regenerative Therapy: New Insights for Old Targets. Pharmaceuticals (Basel) (2017) 0.75
Importance of the REM (Ras exchange) domain for membrane interactions by RasGRP3. Biochim Biophys Acta (2017) 0.75
The protein kinase complement of the human genome. Science (2002) 35.36
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J Mol Biol (1984) 13.69
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 12.18
Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol (2007) 7.20
Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem (2001) 6.42
Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer (2007) 5.71
Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev (2001) 4.38
Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals. Cell (1998) 3.90
Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Cell (1995) 3.08
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem (1993) 2.62
Regulation of cell apoptosis by protein kinase c delta. Apoptosis (2003) 2.60
PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci (2006) 2.46
Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res (2005) 2.42
Protein kinase D: a family affair. FEBS Lett (2003) 2.09
Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization. Mol Cell Biol (1998) 2.08
Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. J Biol Chem (2006) 1.99
Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene (2001) 1.99
Taxonomy and function of C1 protein kinase C homology domains. Protein Sci (1997) 1.98
C1 domains exposed: from diacylglycerol binding to protein-protein interactions. Biochim Biophys Acta (2006) 1.98
Studies on the mechanism of skin tumor promotion: evidence for several stages in promotion. Proc Natl Acad Sci U S A (1980) 1.94
Regulation of transmitter release by Unc-13 and its homologues. Curr Opin Neurobiol (2000) 1.83
A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem (1992) 1.80
Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. Cell (2004) 1.79
A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res (2006) 1.67
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2007) 1.63
Protein kinase Cdelta and apoptosis. Biochem Soc Trans (2007) 1.59
Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res (2001) 1.55
Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem (1994) 1.55
Divergence and complexities in DAG signaling: looking beyond PKC. Trends Pharmacol Sci (2003) 1.52
Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest (2003) 1.49
Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J Virol (2003) 1.47
Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta (1998) 1.45
Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res (2007) 1.42
Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood (2005) 1.41
Signaling roles of diacylglycerol kinases. J Cell Biochem (2006) 1.40
Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood (2003) 1.37
Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J Biol Chem (1999) 1.36
Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis (1985) 1.36
Three distinct mechanisms for translocation and activation of the delta subspecies of protein kinase C. Mol Cell Biol (1998) 1.32
Protein kinase C as a therapeutic target. Clin Cancer Res (2006) 1.31
Regulation of Ras in lymphocytes: get a GRP. Biochem Soc Trans (2006) 1.29
Classical PKC isoforms in cancer. Pharmacol Res (2007) 1.29
Diacylglycerol-induced membrane targeting and activation of protein kinase Cepsilon: mechanistic differences between protein kinases Cdelta and Cepsilon. J Biol Chem (2005) 1.28
Diacylglycerol kinase zeta regulates Ras activation by a novel mechanism. J Cell Biol (2001) 1.28
Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C). Acc Chem Res (2003) 1.28
Roles of ionic residues of the C1 domain in protein kinase C-alpha activation and the origin of phosphatidylserine specificity. J Biol Chem (2000) 1.25
The guanine nucleotide exchange factor RasGRP is a high -affinity target for diacylglycerol and phorbol esters. Mol Pharmacol (2000) 1.24
Activation of RasGRP3 by phosphorylation of Thr-133 is required for B cell receptor-mediated Ras activation. Proc Natl Acad Sci U S A (2004) 1.22
Diacylglycerol kinase iota regulates Ras guanyl-releasing protein 3 and inhibits Rap1 signaling. Proc Natl Acad Sci U S A (2005) 1.21
Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res (1993) 1.20
A novel diacylglycerol-lactone shows marked selectivity in vitro among C1 domains of protein kinase C (PKC) isoforms alpha and delta as well as selectivity for RasGRP compared with PKCalpha. J Biol Chem (2005) 1.13
Association of diacylglycerol kinase zeta with protein kinase C alpha: spatial regulation of diacylglycerol signaling. J Cell Biol (2003) 1.11
Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res (1999) 1.11
PKCdelta signaling: mechanisms of DNA damage response and apoptosis. Cell Signal (2007) 1.08
Dynamic phospholipid signaling by G protein-coupled receptors. Biochim Biophys Acta (2006) 1.06
Conformationally constrained analogues of diacylglycerol. 24. Asymmetric synthesis of a chiral (R)-DAG-lactone template as a versatile precursor for highly functionalized DAG-lactones. Org Lett (2004) 1.05
Expression of a catalytically inactive form of diacylglycerol kinase alpha induces sustained signaling through RasGRP. FASEB J (2002) 1.04
Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol Pharmacol (1994) 1.04
Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activities. J Med Chem (2008) 1.04
Phorbol esters and neurotransmitter release: more than just protein kinase C? Br J Pharmacol (2003) 1.03
The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein. J Biol Chem (2000) 1.03
Contribution of the C1A and C1B domains to the membrane interaction of protein kinase C. Biochemistry (2003) 1.02
Targeting protein kinase C and "non-kinase" phorbol ester receptors: emerging concepts and therapeutic implications. Biochim Biophys Acta (2005) 1.02
The origin of C1A-C2 interdomain interactions in protein kinase Calpha. J Biol Chem (2005) 1.02
Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? J Med Chem (2000) 1.01
Protein kinase Cepsilon and development of squamous cell carcinoma, the nonmelanoma human skin cancer. Mol Carcinog (2006) 1.01
A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters. Mol Cell Biol (2004) 1.01
PKCdelta associates with and is involved in the phosphorylation of RasGRP3 in response to phorbol esters. Mol Pharmacol (2004) 1.00
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs (2007) 0.99
Intermolecular and intramolecular interactions regulate catalytic activity of myotonic dystrophy kinase-related Cdc42-binding kinase alpha. Mol Cell Biol (2001) 0.99
Chimaerins, novel non-protein kinase C phorbol ester receptors, associate with Tmp21-I (p23): evidence for a novel anchoring mechanism involving the chimaerin C1 domain. J Biol Chem (2001) 0.97
New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha. J Med Chem (2003) 0.96
Enzastaurin. Curr Opin Oncol (2007) 0.96
Role of phorbol ester localization in determining protein kinase C or RasGRP3 translocation: real-time analysis using fluorescent ligands and proteins. Mol Cancer Ther (2005) 0.93
Characterization of the interaction of phorbol esters with the C1 domain of MRCK (myotonic dystrophy kinase-related Cdc42 binding kinase) alpha/beta. J Biol Chem (2008) 0.93
Non-promoting 12-deoxyphorbol 13-esters as potent inhibitors of phorbol 12-myristate 13-acetate-induced acute and chronic biological responses in CD-1 mouse skin. Carcinogenesis (1992) 0.92
Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. Cancer Res (1991) 0.92
Tumor promoter binding of the protein kinase C C1 homology domain peptides of RasGRPs, chimaerins, and Unc13s. Bioorg Med Chem (2004) 0.90
Functional PKC in vivo analysis using deficient mouse models. Biochem Soc Trans (2007) 0.89
Differential binding modes of diacylglycerol (DAG) and DAG lactones to protein kinase C (PK-C). J Med Chem (2003) 0.89
Defining the human targets of phorbol ester and diacylglycerol. Curr Opin Mol Ther (2003) 0.89
Rap2B-dependent stimulation of phospholipase C-epsilon by epidermal growth factor receptor mediated by c-Src phosphorylation of RasGRP3. Mol Cell Biol (2004) 0.89
Protein kinase C-beta as a therapeutic target in breast cancer. Semin Oncol (2006) 0.89
Beta2-chimaerin in cancer signaling: connecting cell adhesion and MAP kinase activation. Cell Cycle (2007) 0.89
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis. J Med Chem (2001) 0.88
Distinctive cellular roles for novel protein kinase C isoenzymes. Curr Pharm Des (2006) 0.86
RasGRP1 overexpression in the epidermis of transgenic mice contributes to tumor progression during multistage skin carcinogenesis. Cancer Res (2007) 0.86
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol (2005) 0.85
[Mode of action of carcinogenic plant components]. Planta Med (1972) 0.85
Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect (2005) 0.85
Structure activity relations of polyfunctional diterpenes of the tigliane type, VI. Irritant and tumor promoting activities of semisynthetic mono and diesters of 12-deoxyphorbol. Planta Med (1984) 0.85
Specific binding to protein kinase C by ingenol and its induction of biological responses. Cancer Res (1992) 0.85
Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. Ann Hematol (2006) 0.84
Structural determinants of phorbol ester binding in synaptosomes: pharmacokinetics and pharmacodynamics. Eur J Pharmacol (1999) 0.84
Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes. Curr Pharm Des (2004) 0.84
Proceedings of the First International Conference on PEP005. Anticancer Drugs (2007) 0.83
Mitochondrial origins. Proc Natl Acad Sci U S A (1985) 8.82
Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature (1996) 7.27
A phylogenetic analysis of the mycoplasmas: basis for their classification. J Bacteriol (1989) 6.66
Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit (2009) 3.32
The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc Natl Acad Sci U S A (2000) 3.16
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol (2000) 2.70
Human beta-defensins. Cell Mol Life Sci (2006) 2.57
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol (2010) 2.39
Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol Cell Biol (2000) 2.35
Congenital poisoning by polychlorinated biphenyls and their contaminants in Taiwan. Science (1988) 2.35
A dedicated cone-beam CT system for musculoskeletal extremities imaging: design, optimization, and initial performance characterization. Med Phys (2011) 2.20
Repair of a specific double-strand break generated within a mammalian chromosome by yeast endonuclease I-SceI. Nucleic Acids Res (1994) 2.17
[Effect of intraocular pressure on glaucomatous damage to the optic nerve]. Ophthalmologe (2014) 2.15
Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem (2001) 2.06
Transillumination-assisted orotracheal intubation: a comparison of the Bonfils fibrescope and the lightwand (Trachlight). Acta Anaesthesiol Scand (2012) 2.02
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res (1999) 1.99
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Sinoatrial node pacemaker activity requires Ca(2+)/calmodulin-dependent protein kinase II activation. Circ Res (2000) 1.85
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem (2000) 1.85
A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem (1992) 1.80
Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol (2000) 1.79
Clostridium ljungdahlii sp. nov., an acetogenic species in clostridial rRNA homology group I. Int J Syst Bacteriol (1993) 1.65
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem (2000) 1.65
Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem (1994) 1.63
Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes (1999) 1.60
Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol (2001) 1.55
Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes (2001) 1.54
Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene (2001) 1.54
The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol (2000) 1.50
Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res (1997) 1.50
Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer (2012) 1.49
3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun (1986) 1.48
Global folds of proteins with low densities of NOEs using residual dipolar couplings: application to the 370-residue maltodextrin-binding protein. J Mol Biol (2000) 1.48
Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis (2003) 1.46
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Orienting domains in proteins using dipolar couplings measured by liquid-state NMR: differences in solution and crystal forms of maltodextrin binding protein loaded with beta-cyclodextrin. J Mol Biol (2000) 1.43
Prevalence of abdominal aortic aneurysms in men with diabetes. Med J Aust (1997) 1.42
Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol (1995) 1.42
Percutaneous vasal sperm aspiration and intrauterine insemination in the treatment of obstructive azoospermia. Fertil Steril (1997) 1.41
Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J Virol (1998) 1.41
Human DNA polymerase kappa synthesizes DNA with extraordinarily low fidelity. Nucleic Acids Res (2000) 1.41
Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood (2000) 1.40
Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett (1994) 1.39
Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem (2000) 1.38
Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J Biol Chem (1999) 1.36
Dynamic redistribution of calmodulin in HeLa cells during cell division as revealed by a GFP-calmodulin fusion protein technique. J Cell Sci (1999) 1.36
Residues in the second cysteine-rich region of protein kinase C delta relevant to phorbol ester binding as revealed by site-directed mutagenesis. J Biol Chem (1995) 1.33
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene (2011) 1.31
Crystal structures of B-DNA with incorporated 2'-deoxy-2'-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability. Nucleic Acids Res (1998) 1.29
Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest (1995) 1.29
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. Bioorg Med Chem Lett (2001) 1.26
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res (1999) 1.26
Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2000) 1.26
Crystal structure of a bovine neurophysin II dipeptide complex at 2.8 A determined from the single-wavelength anomalous scattering signal of an incorporated iodine atom. Proc Natl Acad Sci U S A (1991) 1.24
Temporal relationship between cytochrome c release and mitochondrial swelling during UV-induced apoptosis in living HeLa cells. J Cell Sci (2001) 1.24
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol (2008) 1.24
Review: modulating factors in amyloid-beta fibril formation. J Struct Biol (2000) 1.23
ATM--a key determinant of multiple cellular responses to irradiation. Acta Oncol (2001) 1.23
The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene (2006) 1.22
SEK1/MKK4 is required for maintenance of a normal peripheral lymphoid compartment but not for lymphocyte development. Immunity (1998) 1.22
Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21
Brain activation in the processing of Chinese characters and words: a functional MRI study. Hum Brain Mapp (2000) 1.21
Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunol Rev (2000) 1.20
The case for relationship of the flavobacteria and their relatives to the green sulfur bacteria. Syst Appl Microbiol (1990) 1.20
Genetic screens in mammalian cells by enhanced retroviral mutagens. Oncogene (2000) 1.20
beta2-chimaerin is a novel target for diacylglycerol: binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain. Proc Natl Acad Sci U S A (1999) 1.19
Identification of sensitive and specific avian influenza polymerase chain reaction methods through blind ring trials organized in the European Union. Avian Dis (2007) 1.17
A meta-analysis of soyfoods and risk of stomach cancer: the problem of potential confounders. Cancer Epidemiol Biomarkers Prev (2000) 1.16
Application of the fluorescence resonance energy transfer method for studying the dynamics of caspase-3 activation during UV-induced apoptosis in living HeLa cells. Biochem Biophys Res Commun (2001) 1.16
3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol (1986) 1.16
Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis. Substrate cycling between glycerol and triose phosphates in liver. J Biol Chem (1995) 1.15
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med (1998) 1.15
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia (2013) 1.15
Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension (1997) 1.14
Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol (2001) 1.12
Functional Fas ligand expression in thyrocytes from patients with Graves' disease. J Clin Endocrinol Metab (1999) 1.11
Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol (1996) 1.11
Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A. Curr Biol (1999) 1.11
A molecular biology-based approach to resolve the subunit orientation of lipoprotein lipase. Proc Natl Acad Sci U S A (1997) 1.11
Identification of domains in rubella virus genomic RNA and capsid protein necessary for specific interaction. J Virol (1996) 1.11
Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol (1998) 1.10
Modification of viral myocarditis in mice by interleukin-6. Circ Res (1996) 1.10
Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer (2004) 1.09
Volatiles from Ficus hispida and their attractiveness to fig wasps. J Chem Ecol (2001) 1.09
Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation. Conf Proc IEEE Eng Med Biol Soc (2006) 1.09
Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br J Pharmacol (2000) 1.09
Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine. J Mol Biol (1999) 1.09
Carbocyclic nucleosides. Med Res Rev (1986) 1.09
Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist (2001) 1.09
Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene (2011) 1.08
Status of persistent organic pollutants in the sediment from several estuaries in China. Environ Pollut (2001) 1.08
Zonation of acetate labeling across the liver: implications for studies of lipogenesis by MIDA. Am J Physiol (1999) 1.07
Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J Appl Microbiol (2010) 1.07
Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res (1992) 1.07
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol (1992) 1.07
Host gene regulation during coxsackievirus B3 infection in mice: assessment by microarrays. Circ Res (2000) 1.07